| Drug / Therapy | Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Ba |
| Indication | — |
| Decision Type | Phase 1 |
| Trial Phase | Phase 1 |
| ClinicalTrials.gov | NCT06053242 |
Disc Medicine (IRON) operates in the Hematology sector. The current BTS Score is 31 (Grade: F).
Biotech companies frequently raise capital through secondary offerings, ATM programs, and convertible notes. Before or after major FDA decisions, dilution events are common. Understanding a company's dilution history is critical for managing risk around catalyst dates.
The Phase 1 date for Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Ba by Disc Medicine (IRON) is scheduled for May 1, 2026. This is the target date for the FDA to make a decision on this application.
Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Ba is being developed by Disc Medicine for the treatment of its target indication. It is currently in Phase 1 clinical trials.
If Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Ba receives FDA approval, Disc Medicine (IRON) would be able to market the drug in the United States for its target indication. This typically leads to significant stock price movement for biotech companies. Investors should monitor the Phase 1 date closely.
Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for IRON on DilutionWatch at dilutionwatch.com/stock/IRON.html.
You can view the full BiotechSign company profile for Disc Medicine (IRON) at biotechsign.com/app/company/IRON, which includes the BTS Score, signal history, clinical trial data, and insider trading activity.
This page is for informational purposes only and does not constitute investment advice. FDA decision dates are subject to change. Clinical trial outcomes are inherently uncertain. Biotech stocks are highly volatile — past performance does not guarantee future results. Always consult a qualified financial advisor before making investment decisions. BiotechSign is not a registered investment advisor.